Clinical Trials Logo

Filter by:
NCT ID: NCT03584126 Recruiting - Atrial Fibrillation Clinical Trials

Imaging-based, Non-invasive Diagnosis of Persistent Atrial Fibrillation

imATFIB
Start date: April 25, 2017
Phase:
Study type: Observational

The main objective of the present project is to develop an imaging-based tool to determine the origin and cause of persistent atrial fibrillation (AF). The result of the study is a diagnostic method which aids the medical work-up of patients suffering from this disease.

NCT ID: NCT03573297 Recruiting - Depression Clinical Trials

A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features

Start date: June 15, 2018
Phase: Phase 3
Study type: Interventional

1) To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/d compared with placebo in prevention of relapse in patients with bipolar I disorder whose current episode (i.e. index episode) is manic or depressive, with or without mixed features; 2) To evaluate the efficacy and safety of cariprazine at a target dose of 1.5 mg/d compared with placebo in prevention of relapse in patients with bipolar I disorder whose current episode (i.e. index episode) is manic or depressive, with or without mixed features who were initially stabilized on a target dose of 3.0 mg/d

NCT ID: NCT03567421 Recruiting - Stone, Kidney Clinical Trials

Ureteral Stenting After Ureteroscopy for Stone Treatment, A Global Perspective on Indications and Outcomes

Start date: June 7, 2018
Phase:
Study type: Observational [Patient Registry]

Background: The exit strategy after ureteroscopy for stone treatment remains a topic for discussion. Current EAU guidelines on urolithiasis state that postoperative stenting is indicated in patients at increased risk of postoperative complications. Stenting is not considered necessary in all other cases, and after uncomplicated procedures. Objective: To analyse the postoperative ureteral stenting strategy in clinical practice looking at the indication, type of stents used and the duration of stenting after ureteroscopy for stone treatment. Furthermore, the investigators will examine in what setting the stents are being removed postoperatively. Study design: This study is a prospective, observational, international, multicentre registry study executed by uCARE. Study population: All patients >18 years with a ureter or renal stone who are planned for ureteroscopic treatment by semi-rigid and/or flexible ureteroscopy are eligible for this study.

NCT ID: NCT03563716 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study of MTIG7192A in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Start date: June 30, 2018
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of MTIG7192A plus Atezolizumab compared with placebo plus atezolizumab in chemotherapy-naive patients with locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), excluding patients with a sensitizing EGFR mutation or ALK translocation.

NCT ID: NCT03552250 Enrolling by invitation - Clinical trials for Child Mental Disorder

Prevention of Child Mental Health Problems in Southeastern Europe

RISE
Start date: April 26, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to develop an adapted version of a low-cost parenting program (Parenting for Lifelong Health for Young Children, PLH) to the specific needs of families in three low- and middle income countries (LMICs) in southeastern Europe (Romania, FYR of Macedonia and Republic of Moldova). The investigators want systematically evaluate key barriers and facilitators at the local, national and international levels that impact prevention of child behavioral disorders. The investigators will prepare training materials adapted to Romanian, Moldovian, Albanian, Macedonian, and Russian and train facilitators and mentor coaches in the delivery of the PLH program in each country. Also, a pre-post study will be conducted testing the feasibility of the program and the evaluation and implementation methods with 40 families at each country site. This includes examination of outcomes related to implementation fidelity, program acceptability, and preliminary program effectiveness on reducing child behavior problems and associated risk factors. This feasibility study is part of a larger implementation project. Developed on the MOST framework (the multiphase optimization strategy), this specific study will reflect the implementation of the first phase. There are two more phases to come: the Parenting for Lifelong Health for Young Children program will be optimized within the three countries by determining which components are most efficacious and cost-effective (phase 2). The optimized PLH programs will be tested in three RCTS in the countries (phase 3).

NCT ID: NCT03548415 Recruiting - Acromegaly Clinical Trials

Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in up to 42 Adult Patients With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

Start date: July 2018
Phase: Phase 2
Study type: Interventional

The purpose is to assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in up to 42 Patients with Acromegaly

NCT ID: NCT03547271 Not yet recruiting - Clinical trials for Meningococcal Infections

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Start date: November 2018
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to demonstrate the non-inferiority of the antibody response against meningococcal serogroups A, C, Y, and W following a 3-dose series of MenACYW conjugate vaccine compared to a 3-dose series of a licensed meningococcal vaccine, Nimenrix®, when each vaccine is given concomitantly with routine pediatric vaccines to infants and toddlers 6 weeks to 18 months old. The secondary objectives are: - To demonstrate the non-inferiority of the antibody response against meningococcal serogroups A, C, Y, and W following 2 doses in infancy of MenACYW conjugate vaccine compared to 2 doses of Nimenrix® when each vaccine is given concomitantly with routine pediatric vaccines. - To describe the antibody responses against meningococcal serogroups A, C, Y, and W when MenACYW conjugate vaccine is administered in a 3-dose series concomitantly with routine pediatric vaccines. - To describe the antibody responses against the antigens of the routine pediatric vaccines administered in a 3-dose series concomitantly with MenACYW conjugate vaccine or Nimenrix®. - To describe the safety profile of MenACYW conjugate vaccine and Nimenrix®.

NCT ID: NCT03546088 Recruiting - Airway Management Clinical Trials

Awake Nasal Intubation in Laryngopharyngeal Tumors

Start date: February 20, 2018
Phase: N/A
Study type: Interventional

This study evaluates the efficiency of awake naso-tracheal intubation and patient satisfaction when using a small diameter flexible nasolaryngoscope together with topical anaesthesia and light sedation with a combination of benzodiazepine, fentanyl and droperidol. The selected patients will have difficult airway access because of obstructing oro- and hypo-pharynx tumours.

NCT ID: NCT03543917 Recruiting - Clinical trials for Cerebrovascular Accident

Post-Stroke Improvement of Motor Function

PSIOM
Start date: August 8, 2017
Phase: Phase 1
Study type: Interventional

Open-label clinical study where all new patients presenting with cerebrovascular accidents and consenting to treatment are given intravenously a new combination of medications. Patients are evaluated neurologically with NIHSS scores before treatment administration and at 1 month after the first treatment. Further evaluations at 6 months after treatment by NIHSS and Barthel scores are ongoing

NCT ID: NCT03537456 Not yet recruiting - Facial Rejuvenation Clinical Trials

Pilot Trial to Assess the Performance and Tolerance of mRDX-02-17 Dermal Filler in the Facial Rejuvenation

Start date: June 30, 2018
Phase: N/A
Study type: Interventional

mRDX-02-17 is a device for facial beauty care composed of hyaluronic acid in a concentration of 1.5% (p/v), as a functional ingredient, recommended for the correction and treatment of wrinkles and dermal depressions. The primary hypothesis of this clinical investigation is that, at 30 days after the 60 days of treatment with mRDX-02-17, the mean WSRS score assessed by the investigator will decrease with at least 0.5 points compared to baseline evaluation.